Evidence map›Paper›PMID 34147529›Full record

ArticleThe Journal of infection2021

Relapse in the first 8 weeks after onset of COVID-19 disease in outpatients: Viral reactivation or inflammatory rebound?

Maaike Buskermolen, Karlijn Te Paske, Janko van Beek, Titia Kortbeek, Hannelore Götz, Ewout Fanoy, Sabiena Feenstra, Jan Hendrik Richardus, Albert Vollaard

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Therapeutics for COVID-19.Nature microbiology · 2023
    Review
  4. Article
  5. Viral and Symptom Rebound in Untreated COVID-19 Infection.medRxiv : the preprint server for health sciences · 2022
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Maaike BuskermolenDepartment of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, Rotterdam, Netherlands. Electronic address: m.buskermolen@rotterdam.nl.
Karlijn Te PaskeDepartment of Infectious Disease Control, Municipal Public Health Service Utrecht, Utrecht, Netherlands.
Janko van BeekViroscience, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Titia KortbeekCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
Hannelore GötzDepartment of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, Rotterdam, Netherlands; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
Ewout FanoyDepartment of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, Rotterdam, Netherlands.
Sabiena FeenstraCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
Jan Hendrik RichardusDepartment of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, Rotterdam, Netherlands; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Albert VollaardCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19HumansOutpatientsRecurrenceSARS-CoV-2Viral Load

Identifiers

PMID34147529
PMCPMC8236092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.